Nos partenaires de recherche et exemples de nos travaux

Exemples de partenaires de recherche des secteurs privé et public du Dre Guillemette

National Cancer Institute, USA

National Institutes of Health, USA

Frederick National Laboratory for Cancer Research, USA

Karolinska Institutet, Stockholm, Sweden

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

Boston Children’s Hospital, USA

National Cancer Institute, Italy

Center for Global Health and Diseases and Diseases

University of Southern California Keck School of Medicine, USA

Queen’s University, Canada University of Toronto, Canada

University of Ottawa, Canada

Université Laval, Canada

Université de Montréal, Canada

Université du Québec à Montréal, Canada

Apopharma, Apotex

Kantum pharma Inc

Exemples des travaux publiés – Dre Guillemette 

• Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men.
  Petrick JL, Hyland PL, Caron P, Falk RT, Pfeiffer RM, Dawsey SM, Abnet CC, Taylor PR, Weinstein SJ, Albanes D, Freedman ND, Gapstur SM, Bradwin G, Guillemette C, Campbell PT, Cook MB.J Natl Cancer Inst. 2019 Jan 1;111(1):34-41.
• An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.
  Caron P, Turcotte V, Lévesque E, Guillemette C.J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:249-255. 
• Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.
  Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Lévesque É, Guillemette C.Drug Metab Dispos. 2020 Feb;48(2):75-84.
• A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer.
  Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):701-706.
• Discordance between testosterone measurement methods in castrated prostate cancer patients. Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F.Endocr Connect. 2019 Feb;8(2):132-140.
• Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.
  Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Lévesque É,Guillemette C, Klotz L.Clin Cancer Res. 2018 Nov 1;24(21):5305-5312
• Inactivation of Prostaglandin E₂ as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia.

  Allain EP, Rouleau M, Le T, Vanura K, Villeneuve L, Caron P, Turcotte V, Lévesque E, Guillemette C.Front Oncol. 2019 Jul 4;9:606.
• Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
  Allain EP, Venzl K, Caron P, Turcotte V, Simonyan D, Gruber M, Le T, Lévesque E, Guillemette C, Vanura K.Ann Hematol. 2018 Sep;97(9):1649-1661.

• Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women.

  Audet-Delage Y, Villeneuve L, Grégoire J, Plante M, Guillemette C. Front Endocrinol (Lausanne). 2018 Mar 12;9:87.

  Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.

• Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L,Guillemette C. J Urol. 2020 May;203(5):940-948.
•  Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease.
  Eldridge RC, Wentzensen N, Pfeiffer RM, Brinton LA, Hartge P, Guillemette C, Kemp TJ, Pinto LA, Trabert B.Cancer Causes Control. 2020 Apr;31(4):309-320
• Associations between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Post-Menopausal Women.
  Petrick JL, Florio AA, Zhang X, Zeleniuch-Jacquotte A, Wactawski-Wende J, Van Den Eeden SK, Stanczyk FZ, Simon TG, Sinha R, Sesso HD, Schairer C, Rosenberg L, Rohan TE, Purdue MP, Palmer JR, Linet MS, Liao LM, Lee IM, Koshiol J, Kitahara CM, Kirsh VA, Hofmann JN, Guillemette C, Graubard BI, Giovannucci E, Gaziano JM, Gapster SM, Freedman ND, Engel LS, Chong DQ, Chen Y, Chan AT, Caron P, Buring JE, Bradwin G, Beane Freeman LE, Campbell PT, McGlynn KA.Hepatology. 2019 Dec 5:10.1002/hep.31057.
• Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer. Louise A. Brinton, Tim J. Key, Laurence N. Kolonel, Karin B. Michels, Howard D. Sesso, Giske Ursin, Stephen K. Van Den Eeden, Shannon N. Wood, Roni T. Falk, Dominick Parisi, Chantal Guillemette, Patrick Caron, Véronique Turcotte, Laurel A. Habel, Claudine J. Isaacs, Elio Riboli, Elisabete Weiderpass, and Michael B. Cook Journal Clinical Oncology published online on May 11, 2015;
• Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C. Drug Metab Dispos. 2015 Apr;43(4):611-9.
• Association Between Circulating Levels of Sex Steroid Hormones and Barrett’s Esophagus in Men: A Case-Control Analysis. Cook MB, Wood SN, Cash BD, Young P, Acosta RD, Falk RT, Pfeiffer RM, Hu N, Su H, Wang L, Wang C, Gherman B, Giffen C, Dykes C, Turcotte V, Caron P, Guillemette C, Dawsey SM, Abnet CC, Hyland PL, Taylor PR. Clin Gastroenterol Hepatol. 2015 Apr;13(4):673-82.
• Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C. Clin Cancer Res. 2014 Jun 1;20(11):2971-83.
• Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer. Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C. Clin Cancer Res. 2014 Feb 1;20(3):576-84.
• Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes. Ekström L, Cevenini L, Michelini E, Schulze J, Thörngren JO, Belanger A, Guillemette C, Garle M, Roda A, Rane A. Eur J Clin Invest. 2013 Mar;43(3):248-55.
• Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C. Clin Cancer Res. 2013 Feb 1;19(3):699-709.
• A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients. Laverdière I, Caron P, Couture F, Lévesque E, Guillemette C. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Feb 15;885-886:131-7.
• Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5′-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients. Laverdière I, Caron P, Couture F, Guillemette C, Lévesque E. Anal Chem. 2012 Jan 3;84(1):216-23.
• The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É. Eur Urol. 2012 Jul;62(1):88-96.
• Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. Nadeau G, Bellemare J, Audet-Walsh É, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, Lévesque E. J Clin Endocrinol Metab. 2011 Sep;96(9):E1550-7.
• SRD5A polymorphisms and biochemical failure after radical prostatectomy. Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E. Eur Urol. 2011 Dec;60(6):1226-34.
• Correlation between circulatory, local prostatic, and intra-prostatic androgen levels. Olsson M, Ekström L, Guillemette C, Belanger A, Rane A, Gustafsson O. Prostate. 2011 Jun 15;71(9):909-14.
• In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4.Laverdière I, Caron P, Harvey M, Lévesque É, Guillemette C. Drug Metab Dispos. 2011 Jul;39(7):1127-30.
• Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A, Guillemette C. J Clin Endocrinol Metab. 2011 Feb;96(2):E330-9.
• Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. Lépine J, Audet-Walsh E, Grégoire J, Têtu B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Bélanger A, Guillemette C. J Clin Endocrinol Metab. 2010 Jun;95(6):2689-98.